Omega Funds

Venture Capital

Portfolio

companies

EyeBio

EyeBio develops a pipeline of novel therapies for retinal and eye diseases.

Bernard Davitian

Partner

Series A14 November 2023

£52.0M

EyeBio secures £52m Series A extension from new and existing investors to advance retinal disease pipeline

Bain Capital Life Sciences, Omega Funds and Vertex Ventures HC joined the financing round to support accelerated development of the company pipeline.

"We look forward to partnering with David Guyer and the world-class team at EyeBio to contribute to building a great company together"

— Bernard Davitian, Partner